1. Home
  2. PUBM vs PBYI Comparison

PUBM vs PBYI Comparison

Compare PUBM & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PubMatic Inc.

PUBM

PubMatic Inc.

HOLD

Current Price

$6.50

Market Cap

301.2M

Sector

Technology

ML Signal

HOLD

Logo Puma Biotechnology Inc

PBYI

Puma Biotechnology Inc

HOLD

Current Price

$6.58

Market Cap

263.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PUBM
PBYI
Founded
2006
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
301.2M
263.4M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
PUBM
PBYI
Price
$6.50
$6.58
Analyst Decision
Buy
Strong Buy
Analyst Count
9
1
Target Price
$18.28
$7.00
AVG Volume (30 Days)
645.9K
441.5K
Earning Date
02-26-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
59.87
EPS
N/A
0.74
Revenue
$288,382,000.00
$211,995,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.55
N/A
P/E Ratio
N/A
$8.88
Revenue Growth
N/A
N/A
52 Week Low
$6.21
$2.58
52 Week High
$17.32
$7.29

Technical Indicators

Market Signals
Indicator
PUBM
PBYI
Relative Strength Index (RSI) 28.99 51.87
Support Level $6.21 $6.75
Resistance Level $6.90 $6.98
Average True Range (ATR) 0.31 0.32
MACD -0.04 -0.04
Stochastic Oscillator 16.57 30.24

Price Performance

Historical Comparison
PUBM
PBYI

About PUBM PubMatic Inc.

PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: